The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Marchi E, Ma H, Montanari F, Sawas A, Lue J, Deng C, Whitfield K, Klein S, Scotto L, Jain S, Lister J, Benanni N, Francescone M, Kim W, Zinzani P, O'Connor O. The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Journal Of Clinical Oncology 2020, 38: 8049-8049. DOI: 10.1200/jco.2020.38.15_suppl.8049.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaGrade 3 hyponatremiaPhase 1b studyTreatment-related deathsGrade 3 thrombocytopeniaImmune checkpoint inhibitorsPreliminary clinical dataDose of drugPre-clinical modelsCancer-testis antigensCases of toxicityExperienced progressionFebrile neutropeniaRefractory PTCLStable diseaseComplete remissionPartial remissionPatient characteristicsClinical dataPharmacodynamic studiesTestis antigensPatientsTriple combinationResponse rateLow dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series
Ma H, Cheng B, Montanari F, Lue JK, Deng C, Marchi E, Connor O, Sawas A. Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. Therapeutic Advances In Hematology 2020, 11: 2040620720947340. PMID: 33062232, PMCID: PMC7534065, DOI: 10.1177/2040620720947340.Peer-Reviewed Original ResearchAutologous stem cell transplantClassical Hodgkin lymphomaR cHLRefractory classical Hodgkin lymphomaStable diseasePartial responseComplete responseHodgkin's lymphomaPatient populationToxicity profileHigher disease control rateMedian progression-free survivalAlanine transaminase elevationClinical benefit rateLeast equivalent efficacyDisease control rateProgression-free survivalRetrospective case seriesStem cell transplantTolerable toxicity profileFavorable safety profileFavorable toxicity profileContinuous lenalidomideCreatinine elevationTransaminase elevation